MX2018000592A - Derivados de etinilo como moduladores del receptor de glutamato metabotropico. - Google Patents
Derivados de etinilo como moduladores del receptor de glutamato metabotropico.Info
- Publication number
- MX2018000592A MX2018000592A MX2018000592A MX2018000592A MX2018000592A MX 2018000592 A MX2018000592 A MX 2018000592A MX 2018000592 A MX2018000592 A MX 2018000592A MX 2018000592 A MX2018000592 A MX 2018000592A MX 2018000592 A MX2018000592 A MX 2018000592A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor modulators
- glutamate receptor
- metabotropic glutamate
- salt
- compounds
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula I: (ver Fórmula) en la que R1 es alquilo inferior, R2 es fenilo o piridinilo, en el que el átomo de N en el grupo piridinilo puede encontrarse en posiciones diferentes, n es 0, 1 ? 2, V/U son, independientemente, O o CH2, en los que V y U no pueden ser simultáneamente O, L es un grupo heteroarilo de cinco o seis elementos, seleccionado de entre: (ver Fórmulas) o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o estereoisómero correspondiente de los mismos. Los compuestos pueden utilizarse para el tratamiento de la enfermedad de Parkinson, la ansiedad, la emesis, el trastorno obsesivo-compulsivo, el autismo, la neuroprotección, el cáncer, la depresión y la diabetes de tipo 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176854 | 2015-07-15 | ||
| PCT/EP2016/066393 WO2017009275A1 (en) | 2015-07-15 | 2016-07-11 | Ethynyl derivatives as metabotropic glutamate receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018000592A true MX2018000592A (es) | 2018-04-24 |
| MX374409B MX374409B (es) | 2025-03-04 |
Family
ID=53758003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018000592A MX374409B (es) | 2015-07-15 | 2016-07-11 | Derivados de etinilo como moduladores del receptor de glutamato metabotrópico. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10189848B2 (es) |
| EP (1) | EP3322701B1 (es) |
| JP (1) | JP6761821B2 (es) |
| KR (1) | KR20180026438A (es) |
| CN (1) | CN107580598B (es) |
| AR (1) | AR105341A1 (es) |
| AU (1) | AU2016292863B2 (es) |
| CA (1) | CA2984711C (es) |
| CL (1) | CL2018000036A1 (es) |
| CO (1) | CO2017011174A2 (es) |
| CR (1) | CR20180022A (es) |
| DK (1) | DK3322701T3 (es) |
| ES (1) | ES2733468T3 (es) |
| HR (1) | HRP20191139T1 (es) |
| HU (1) | HUE045145T2 (es) |
| IL (1) | IL255096B (es) |
| LT (1) | LT3322701T (es) |
| MA (1) | MA42442B1 (es) |
| MX (1) | MX374409B (es) |
| PE (1) | PE20180356A1 (es) |
| PH (1) | PH12018500106A1 (es) |
| PL (1) | PL3322701T3 (es) |
| PT (1) | PT3322701T (es) |
| RS (1) | RS58929B1 (es) |
| RU (1) | RU2721776C9 (es) |
| SI (1) | SI3322701T1 (es) |
| TR (1) | TR201909160T4 (es) |
| TW (1) | TWI612962B (es) |
| UA (1) | UA120463C2 (es) |
| WO (1) | WO2017009275A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ702747A (en) | 2012-06-13 | 2017-03-31 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| HUE045145T2 (hu) | 2015-07-15 | 2019-12-30 | Hoffmann La Roche | Etinil-származékok metabotróp glutamátreceptor-modulátorokként |
| JP6936305B2 (ja) | 2016-07-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | エチニル誘導体 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| CN112566906B (zh) | 2018-07-26 | 2024-11-12 | 多曼治疗学公司 | 取代的喹唑啉酮衍生物和它们作为mglur4的正变构调节剂的用途 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| KR20250156792A (ko) * | 2023-03-10 | 2025-11-03 | 브라이트씨드, 인크. | 스트레스 조절을 위한 조성물 및 방법 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| MX2007014256A (es) * | 2005-05-24 | 2008-03-26 | Serono Lab | Derivados espiro triciclicos como moduladores crth2. |
| CN101528711A (zh) | 2006-08-31 | 2009-09-09 | 先灵公司 | 可用作抗细菌剂的乙内酰脲衍生物 |
| NZ581817A (en) | 2007-06-03 | 2012-05-25 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| WO2009094755A1 (en) | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
| WO2010081492A1 (en) | 2009-01-19 | 2010-07-22 | Fondazione Ospedale Maggiore Policlinico Mangiagalli Regina Elena - Milano | Melanocortin analogs with antimicrobial activity |
| US9097713B2 (en) | 2009-09-02 | 2015-08-04 | The United States Of America As Represented By The Secretary Of The Army On Behalf Of Usamrmc | Monoclonal antibodies against glycoprotein of Ebola sudan boniface virus |
| IN2012DN02580A (es) | 2009-09-04 | 2015-08-28 | Univ Vanderbilt | |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| PE20141168A1 (es) | 2011-04-26 | 2014-09-22 | Hoffmann La Roche | Derivados de pirazolidin-3-ona |
| HUE025031T2 (en) | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
| US10533000B2 (en) | 2011-05-26 | 2020-01-14 | Sunovion Pharmaceuticals, Inc. | Metabotrophic glutamate receptor 5 modulators and methods of use thereof |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| UA110995C2 (uk) | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| LT2875000T (lt) | 2012-07-17 | 2016-11-10 | F.Hoffmann-La Roche Ag | Ariletinilo dariniai |
| NZ703537A (en) | 2012-10-18 | 2018-06-29 | Hoffmann La Roche | Ethynyl derivatives |
| EP2909179B1 (en) | 2012-10-18 | 2016-10-05 | F. Hoffmann-La Roche AG | Ethynyl derivatives as modulators of mglur5 receptor activity |
| CN105121424B (zh) | 2013-02-18 | 2019-01-22 | 华领医药技术（上海）有限公司 | mGluR调节剂 |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| KR101757603B1 (ko) * | 2013-09-25 | 2017-07-12 | 에프. 호프만-라 로슈 아게 | 에틴일 유도체 |
| TWI649310B (zh) | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| CA2939572A1 (en) | 2014-02-19 | 2015-08-27 | Jody Berry | Marburg monoclonal antibodies |
| UA117855C2 (uk) | 2014-02-25 | 2018-10-10 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| CA2963470A1 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| JP6539749B2 (ja) | 2015-03-19 | 2019-07-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ｍＧｌｕＲ４のモジュレーターとしての３−（４−エチニルフェニル）ヘキサヒドロピリミジン−２，４−ジオン誘導体 |
| HUE045145T2 (hu) | 2015-07-15 | 2019-12-30 | Hoffmann La Roche | Etinil-származékok metabotróp glutamátreceptor-modulátorokként |
| JP6936305B2 (ja) | 2016-07-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | エチニル誘導体 |
-
2016
- 2016-07-11 HU HUE16739442A patent/HUE045145T2/hu unknown
- 2016-07-11 EP EP16739442.8A patent/EP3322701B1/en active Active
- 2016-07-11 PT PT16739442T patent/PT3322701T/pt unknown
- 2016-07-11 DK DK16739442.8T patent/DK3322701T3/da active
- 2016-07-11 CN CN201680026777.2A patent/CN107580598B/zh active Active
- 2016-07-11 ES ES16739442T patent/ES2733468T3/es active Active
- 2016-07-11 MA MA42442A patent/MA42442B1/fr unknown
- 2016-07-11 AU AU2016292863A patent/AU2016292863B2/en not_active Ceased
- 2016-07-11 KR KR1020187000004A patent/KR20180026438A/ko active Pending
- 2016-07-11 CA CA2984711A patent/CA2984711C/en active Active
- 2016-07-11 PL PL16739442T patent/PL3322701T3/pl unknown
- 2016-07-11 PE PE2017002337A patent/PE20180356A1/es unknown
- 2016-07-11 UA UAA201801133A patent/UA120463C2/uk unknown
- 2016-07-11 HR HRP20191139TT patent/HRP20191139T1/hr unknown
- 2016-07-11 LT LTEP16739442.8T patent/LT3322701T/lt unknown
- 2016-07-11 SI SI201630292T patent/SI3322701T1/sl unknown
- 2016-07-11 RU RU2018103944A patent/RU2721776C9/ru active
- 2016-07-11 TR TR2019/09160T patent/TR201909160T4/tr unknown
- 2016-07-11 CR CR20180022A patent/CR20180022A/es unknown
- 2016-07-11 JP JP2017564709A patent/JP6761821B2/ja active Active
- 2016-07-11 RS RS20190819A patent/RS58929B1/sr unknown
- 2016-07-11 WO PCT/EP2016/066393 patent/WO2017009275A1/en not_active Ceased
- 2016-07-11 MX MX2018000592A patent/MX374409B/es active IP Right Grant
- 2016-07-13 AR ARP160102117A patent/AR105341A1/es unknown
- 2016-07-14 TW TW105122266A patent/TWI612962B/zh active
-
2017
- 2017-10-17 IL IL255096A patent/IL255096B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011174A patent/CO2017011174A2/es unknown
-
2018
- 2018-01-05 CL CL2018000036A patent/CL2018000036A1/es unknown
- 2018-01-12 PH PH12018500106A patent/PH12018500106A1/en unknown
- 2018-01-12 US US15/869,268 patent/US10189848B2/en active Active
- 2018-12-14 US US16/220,512 patent/US11034699B2/en active Active
-
2021
- 2021-05-09 US US17/315,349 patent/US12006323B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018000592A (es) | Derivados de etinilo como moduladores del receptor de glutamato metabotropico. | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| EA201691046A1 (ru) | Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) | |
| AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| IN2014CN02478A (es) | ||
| AR097721A1 (es) | Derivados de etinilo | |
| MX2018014944A (es) | Tratamiento para la enfermedad de parkinson. | |
| AR093042A1 (es) | Derivados de etinilo | |
| EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| EA201391538A1 (ru) | Производные пиразолидин-3-она | |
| AR104863A1 (es) | Derivados imidazol | |
| CO2017011010A2 (es) | Derivados de etinilo | |
| CO2018013824A2 (es) | Derivados de etinilo | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| AR105327A1 (es) | Derivados de imidazol | |
| AR093029A1 (es) | Derivados de etilino | |
| CO7180198A2 (es) | Ariletinilo pirimidinas | |
| TH1701007595A (th) | อนุพันธ์เอไทนิลในฐานะโมดูเลเตอร์ของเมทาโบโทรปิกกลูตาเมตรีเซปเตอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |